These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7579948)

  • 21. Dyslipidemic hypertension: distinctive features and cardiovascular risk in a prospective population-based study.
    Onat A; Hergenç G; Sari I; Türkmen S; Can G; Sansoy V
    Am J Hypertens; 2005 Mar; 18(3):409-16. PubMed ID: 15797662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentially modifiable classic risk factors and their impact on incident myocardial infarction: results from the EPIC-Potsdam study.
    Heidemann C; Hoffmann K; Klipstein-Grobusch K; Weikert C; Pischon T; Hense HW; Boeing H
    Eur J Cardiovasc Prev Rehabil; 2007 Feb; 14(1):65-71. PubMed ID: 17301629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Reactive metabolites of oxygen, lipid peroxidation, total antioxidant capacity and vitamin E in essential arterial hypertension].
    Digiesi V; Oliviero C; Giannò V; Rossetti M; Fiorillo C; Oradei A; Lenuzza M; Nassi P
    Clin Ter; 1997 Nov; 148(11):515-9. PubMed ID: 9494252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD144(+)EMPs/CD62E(+)EMPs: a couple of new biomarkers to monitor endothelial function in hypertension with hyperlipidemia involved.
    Hu SS; Zhang HG; Zhang QJ; Xiu RJ
    Int J Cardiol; 2014 Jul; 175(1):203. PubMed ID: 24820735
    [No Abstract]   [Full Text] [Related]  

  • 25. Hypertension and lipids.
    Sznajderman M
    Blood Press Suppl; 1996; 1():14-7. PubMed ID: 9162431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population.
    Dassanayake AS; Kasturiratne A; Rajindrajith S; Kalubowila U; Chakrawarthi S; De Silva AP; Makaya M; Mizoue T; Kato N; Wickremasinghe AR; de Silva HJ
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1284-8. PubMed ID: 19476560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid profile and apolipoprotein E polymorphism in essential hypertension.
    Bhavani AB; Sastry KB; Reddy NK; Padma T
    Indian Heart J; 2005; 57(2):151-7. PubMed ID: 16013355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Estimation of the number of patients treated for hypertension, diabetes or hyperlipidemia in France: FLAHS study 2002].
    Girerd X; Mourad JJ; Vaïsse B; Poncelet P; Mallion JM; Herpin D
    Arch Mal Coeur Vaiss; 2003; 96(7-8):750-3. PubMed ID: 12945216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The prevalence of arterial hypertension in different types of dyslipidemia in various age groups].
    Dmitrenko SA
    Lik Sprava; 1999 Sep; (6):21-3. PubMed ID: 10626433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease.
    Johnson ML; Pietz K; Battleman DS; Beyth RJ
    Am J Manag Care; 2004 Dec; 10(12):926-32. PubMed ID: 15617368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease.
    Vassalle C; Botto N; Andreassi MG; Berti S; Biagini A
    Coron Artery Dis; 2003 May; 14(3):213-8. PubMed ID: 12702924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total cardiovascular risk estimation in Romania. Data from the SEPHAR study.
    Dorobantu M; Bădilă E; Ghiorghe S; Darabont RO; Olteanu M; Flondor P
    Rom J Intern Med; 2008; 46(1):29-37. PubMed ID: 19157268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of adiponectin with procollagen type I carboxyterminal propeptide in non-diabetic essential hypertension.
    Tsai WC; Lin CC; Chen JY; Huang YY; Lee CH; Li WT; Weng CM; Chen JH
    Blood Press; 2008; 17(4):233-8. PubMed ID: 18671144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral hepatitis in Bucharest.
    Paquet C; Babes VT; Drucker J; Sénémaud B; Dobrescu A
    Bull World Health Organ; 1993; 71(6):781-6. PubMed ID: 8313496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The "absolute" cardiovascular risk].
    Hannedouche T; Bouiller M; Caillard S
    Nephrologie; 1998; 19(4):191-5. PubMed ID: 9675758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum lipids, lipoproteins and apolipoproteins in untreated essential hypertension.
    Donma O; Donma MM; Kahraman D; Uygur H; Sagliker Y
    J Hum Hypertens; 1993 Jun; 7(3):311-3. PubMed ID: 8345503
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hyperuricemia as a risk factor for noninfectious diseases in the inhabitants of Chuvashia].
    Madianov IV; Balabolkin MI; Saperov VN; Markov DS; Oreshnikov EV; Grigor'ev AA; Markova TN
    Ter Arkh; 1997; 69(6):49-51. PubMed ID: 9297274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease.
    Perreault S; Dorais M; Coupal L; Paradis G; Joffres MR; Grover SA
    CMAJ; 1999 May; 160(10):1449-55. PubMed ID: 10352634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use.
    Novak S; Melkonian AK; Patel PA; Kleinman NL; Joseph-Ridge N; Brook RA
    Curr Med Res Opin; 2007 Mar; 23(3):623-30. PubMed ID: 17355743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of arterial hypertension in a collectivity of adolescents.
    Munteanu D; Schioiu-Costache L; Niţă I; Serban M; Purice S
    Med Interne; 1990; 28(3):241-3. PubMed ID: 2092395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.